Table 1 Demographic, clinical, and laboratory features of systemic sclerosis patients and controls
Systemic sclerosis patients (n = 50) | Healthy controls (n = 38) | |
|---|---|---|
Female gender (%) | 47 (94.0) a | 36 (94.7) a |
Age (years) | 57.2 ± 12.8 b | 55.2 ± 11.4 b |
European-derived (%) | 40 (80) | 24 (68.6) |
Smoking status (%) | ||
Never | 25 (50) | 23 (65.7) |
Previous | 21 (42) | 30 (29.7) |
Current | 4 (8) | 2 (5.7) |
Disease duration (years) | 15 (7–21) | |
Diffuse cutaneous involvement (%) | 14 (28.0) | |
Modified Rodnan skin score | 6 (2.8–10.3) | |
Renal crisis | 4 (8.0) | |
Gastrointestinal symptoms (%) | ||
Heartburn | 25 (50.0) | |
Dysphagia | 26 (52.0) | |
Diarrhea / constipation | 21 (42.0) | |
DLCO (% predicted) | 70.1 ± 16.3 | |
Reduced DLCO (< 80% predicted) | 52.9 (15.9) | |
FVC (% predicted) | 79.2 ± 18.9 | |
Reduced FVC (< 80% of predicted) | 22 (44) | |
PASP | 31.7 ± 14.4 | |
Pulmonary hypertension (PASP ≥40 mmHg) (%) | 5 (10) | |
Autoantibodies (%) | ||
ANA | 39/50 (78.0) | |
Anti-Ro/SSA | 1/45 (2.2) | |
Anti-La/SSB | 0/45 (0) | |
Anti-Scl-70 | 4/44 (9.1) | |
RF | 35/50 (75.0) | |
Medications (%) | ||
Prednisolone < 20 mg/day | 6 (12) | |
Mycophenolate mofetil | 4 (8) | |
Previous methotrexate administration | 10 (20) | |
Previous rituximab administration | 2 (4) | |
Previous cyclophosphamide administration | 12 (24) | |